2 unchanged sentences
Our common stock is traded on the NYSE American exchange under the symbol LODE.
−Removed: The last reported sale price of our common stock on the NYSE Amer ican on March 28, 2022, wa s $1.80 per share.
+Added: The last reported sale price of our common stock on the NYSE American on March 16, 2023, was $0.35 per share.
At March 16, 2023, the number of holders of record was 497.
−Removed: T he following table sets forth, for the periods indicated, the range of high and low closing bid prices for Comstock’s common stock as repor ted by the NYSE.
−Removed: The reported bid quotations reflect inter-dealer prices without retail markup, markdown or commissions, and may not necessarily represent actual transactions.
SALE OF UNREGISTERED SECURITIES
−Removed: The Company sold 1,000,000 shares of unregistered securities at a price of $1.40 per common shares, for net proceeds of $1.4 million for the year ended December 31, 2021.
−Removed: The Company did not sell any unregistered securities during 2020.
+Added: On October 25, 2022, the Company issued 605,620 shares of common stock to Alvin Fund LLC for an aggregate sales price of $250,000 at an average price per share of $0.41 in connection with the placement of a $2,000,000 short-term promissory note.
+Added: On October 5, 2022, the Company sold 1,000,000 shares of unregistered securities at a price of $0.375 per common shares for net proceeds of $375,000.
+Added: On August 26, 2022, we issued 802,295 shares of unregistered restricted common stock with a fair value of $482,500 to Northern Comstock LLC as payment for obligations due under the Northern Comstock operating agreement.
+Added: On June 21, 2022, the Company entered into an equity purchase agreement (the “Purchase Agreement”) with Tysadco Partners, LLC (“Tysadco”) for the private placement of 3,076,923 common shares at a purchase price of $0.65 per share.
+Added: The Company paid $140,000 in cash and delivered 57,143 common shares with a fair value of $40,000 to the placement agent in connection with such sale.
+Added: The Company issued 428,571 unregistered common shares with a fair value of $300,000 in commitment fees.
+Added: On May 20, 2022, the Company cancelled 720,000 common shares returned by a previous employee and former owner of MANA.
+Added: On April 12, 2022, the Company issued 136,986 unregistered common shares with a fair value of $200,000 in due diligence fees.
+Added: On April 7, 2022, the Company issued 1,500,000 unregistered common shares with a fair value of $2,050,000 as part of the acquisition of the Haywood Quarry from Decommissioning Services Inc.
+Added: On February 28, 2022, the Company and the other parties to the LP Biosciences transactions mutually agreed to terminate the Transaction Documents.
+Added: In connection with the termination, 3,500,000 restricted shares of the Company’s common stock were transferred back to the Company for cancellation upon receipt.
+Added: On December 30, 2021, the Company issued 3,500,000 shares of unregistered securities at a price of $2.07 per share for the purchase of LINICO Corporation from its founder for $7,258,162 equating to 90% ownership.
+Added: On December 3, 2021, the Company sold 1,000,000 shares of unregistered securities at a price of $1.40 per common shares for net proceeds of $1,400,000.
+Added: On September 27, 2021, the Company issued 8,500,000 unregistered common shares with a fair value of $14,952,806 to the former owners of Plain Sight Innovations Inc.
+Added: for the acquisition of 100% that company.
+Added: On August 27, 2021, we issued 163,156 shares of unregistered common shares with a fair value of $482,500 to Northern Comstock LLC as payment for obligations due under the Northern Comstock operating agreement.
+Added: On July 23, 2021, the Company issued 3,500,000 unregistered common shares to LP Biosciences with a fair value of $10,815,000 as part of a transaction and proposed joint venture.
+Added: On February 28, 2022, the Company and the other parties to the LP Biosciences transactions mutually agreed to terminate the LP Biosciences related transaction documents and the 3,500,000 unregistered common shares were transferred back to the Company and cancelled upon receipt.
+Added: On July 23, 2021, the Company issued 4,200,000 unregistered common shares with a fair value of $6,528,453 to sole former owners of MANA Corporation for the acquisition of 100% that company.
+Added: On June 18, 2021, the Company issued 1,000,000 unregistered common shares with a fair value of $2,304,806 to the sole former owner of Renewable Process Solutions Inc.
+Added: for the acquisition of 100% that company.
+Added: On June 24, 2021, the Company issued 3,000,000 unregistered common shares to Quantum Generative Materials LLC (“GenMat”), with a fair value of $10,530,000 in connection with a strategic investment in GenMat.
+Added: On February 16, 2021, the Company issued 3,000,000 unregistered common shares to LINICO Corporation, with a fair value of $6,750,000 in connection with a strategic investment in LINICO.
EQUITY COMPENSATION PLAN INFORMATION
−Removed: See Item 12, Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters , for information on plans approved by our stockholders.
+Added: See Item 11, Executive Compensation , for information on plans approved by our stockholders.
DIVIDEND POLICY
6 unchanged sentences
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.